Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) Profit After Tax (2016 - 2025)

Acro Biomedical (ACBM) has 10 years of Profit After Tax data on record, last reported at $42526.0 in Q4 2025.

  • For Q4 2025, Profit After Tax rose 498.44% year-over-year to $42526.0; the TTM value through Dec 2025 reached -$101146.0, down 139.13%, while the annual FY2025 figure was -$101146.0, 139.13% down from the prior year.
  • Profit After Tax reached $42526.0 in Q4 2025 per ACBM's latest filing, up from -$117809.0 in the prior quarter.
  • Across five years, Profit After Tax topped out at $42526.0 in Q4 2025 and bottomed at -$4.0 million in Q3 2022.
  • Average Profit After Tax over 5 years is -$1.6 million, with a median of -$456248.0 recorded in 2021.
  • Peak YoY movement for Profit After Tax: plummeted 6503.69% in 2022, then soared 498.44% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$3.9 million in 2021, then fell by 2.12% to -$3.9 million in 2022, then surged by 99.54% to -$18240.0 in 2023, then skyrocketed by 41.49% to -$10673.0 in 2024, then skyrocketed by 498.44% to $42526.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were $42526.0 in Q4 2025, -$117809.0 in Q3 2025, and -$15562.0 in Q2 2025.